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Abstract 
Objectives: As more health technology assessment (HTA) bodies seek to implement patient 
involvement, there is a desire to learn from other HTA bodies about their experiences and 
understand what approaches can be used and which ones make a real difference to HTA. This is 
difficult, as the impact of patient involvement in HTA is not well documented. This paper aims to 
promote further discussion about the ways in which patient involvement can impact HTAs by 
studying stories of impact. 
 
Methods: In a multi-stakeholder workshop, experts leading patient involvement in four HTA bodies 
shared examples of HTAs where they felt patient involvement made a difference, then they reflected 
on these impact stories within the wider context of impact evaluation.  
 
Results: The HTA bodies drew on patient input and patient-based evidence to inform their HTAs. The 
patient involvement was observed to elucidate patients’ experiences, needs and preferences which, 
in turn, was observed to influence the HTA recommendations about optimal use of technologies, 
including taking account of issues for sub-groups, outcomes that matter to patients and educational 
needs. 
 
Conclusions: Personal stories of patient involvement may enable a wider understanding of different 
approaches to and impact of patient involvement. The examples relate to both patient input and 
patient-based evidence and highlight the role that patient involvement can play in reducing 
uncertainties and complementing the clinical and economic evidence in HTA. They suggest that 
impact can be seen in recommendations about how and when a technology is used.  
 
Key words: Patient involvement; Impact; Technology Assessment 
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Introduction 
Health technology assessment (HTA) is grounded in rigorous scientific process, focussed on 
quantitative methods to determine clinical, and sometimes cost, effectiveness. As it is intended to 
inform policy, patients have a democratic right to be involved (1). However, misunderstandings 
about the robustness of research into patient aspects and concerns about the biases that patients 
may bring, have led to slow uptake of patient involvement processes. Meanwhile HTA bodies which 
have implemented patient involvement processes are keen to learn from others and understand 
what works best and why, so that they can develop processes that suit their own context. However, 
few HTA bodies have published evaluations of patient involvement and been explicit about the 
outcome or impact of involvement (2,3,4).  
 
The multidisciplinary and deliberative nature of HTA - in which different sources of evidence and 
expert opinion must work together to address a problem - means that identifying a discrete part of 
an HTA process, or cause for an impact, may not be simple. Along with other expert input, patient 
involvement is intended to inform all the elements of an HTA from shaping research questions and 
informing cost effectiveness models to communicating the advice or recommendations. As a result, 
the integration of patient views in recommendations is considered as a measure of impact (5), while 
an increase in recommendations to reimburse or fund the cost of medicines is not (6). 
 
This paper aims to promote further discussion about the ways in which patient involvement can 
impact HTAs, studying particular cases in-depth, using stories told by people who lead the practice in 
HTA bodies. It uses the HTA international (HTAi) definition of patient involvement in HTA and reflects 
on (i) patient participation in HTAs, usually taking the form of patient input, and (ii) research into 
patient aspects, which can be described as patient-based evidence (1). Specifically, these stories 
were told in response to the question of: ‘What difference is patient involvement making to your 
HTAs?’ and their intent was to share learnings with other HTA bodies and all HTA stakeholders. 
 
Methods 
At HTAi’s 2017 Annual Meeting, a one-day interdisciplinary workshop entitled Patient involvement in 
HTA – Why, when and how? was held to present and discuss the book Patient Involvement in HTA 
(7). An important element of this was to hear case studies or stories from HTA bodies about the 
value of patient involvement in their own jurisdiction. 
 
Eight people experienced in patient involvement in HTA bodies were invited to present in one of two 
panels (Table 1). Four were asked to take part in a panel addressing the difference that research in 
patient aspects had made to an HTA and four were asked to form a panel focusing on the difference 
made by patient participation. Presenters were chosen because they represented different HTA 
bodies included as case studies in the book, although they were not necessarily an author of the 
case study. Rather than repeating the content of the book, which provided detailed descriptions of 
organizational patient involvement processes, they were asked to reflect on their personal 
experiences and observations of patient involvement and were given the additional prompt of ‘how 
or when is it adding valuing?’. Subsequently, the presenters provided personal stories or narratives 
of impact from the perspective of someone employed by an HTA body to make sense of the 
experience (8) rather than reports of formal evaluations of impact. In doing so, the stories offered 
their understanding of the impact of patient involvement on an HTA at the time of telling the story. 
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Following the workshop, each of the presenters were invited to document these observations in a 
paper. Four of the eight presenters - from the Scottish Health Technologies Group (SHTG), Canadian 
Agency for Drugs and Technologies in Health (CADTH), England’s National Institute for Health and 
Care Excellence (NICE) and Brazil’s National Committee for Health Technology Incorporation 
(CONITEC) - agreed to take part and four either declined or did not respond to the invitation. A draft 
paper based on notes from the presentations was prepared by one of the authors (AS). The four 
presenters then used this draft as an aid to further reflection on the topic, including discussions with 
colleagues in their organizations, and redrafted the paper accordingly.  
 
Results 
The HTA bodies included in this paper employ a variety of approaches to patient involvement, which 
are summarised in Table 2. 
 
Patient-based evidence for antimicrobial wound dressings (SHTG)  
SHTG, part of Healthcare Improvement Scotland, assesses non-medicine health technologies - such 
as devices, diagnostics and changes to treatment pathways - predominantly in rapid HTAs of clinical 
and cost-effectiveness. It also undertakes some full HTAs which have time scales and resources that 
allow it to follow the Danish model of HTA (9) that includes thorough evaluation of patient aspects 
and organizational issues alongside clinical and cost effectiveness.  
 
Patient involvement in HTAs of non-medicine technologies can be challenging. Often there is no 
clear patient group to participate in these HTAs and patients may be unaware of the specific 
intervention used. However, patients’ needs, preferences, and experiences can be essential to 
ensure non-medicine health technologies are administered optimally. 
 
SHTG’s HTA of antimicrobial wound dressings in patients with chronic leg ulcers (10) demonstrates 
the way in which patient-based evidence can provide essential evidence to formulate conclusions 
and develop relevant advice. SHTG found wide variability in the type of antimicrobial wound 
dressings used in each health board in Scotland, and uncertainty in the clinical and cost effectiveness 
of these dressings. To identify sufficient literature relating to patient perspectives and values, SHTG 
iteratively developed a literature search (11), adding terminology to capture people living with 
chronic wounds and any type of wound dressings. 
 
Additionally, SHTG conducted one focus group (n=8) and six telephone interviews with people in 
Scotland. Thirteen of the participants had experienced chronic wound treatment with antimicrobial 
wound dressings and one participant was a relative of a person who had experienced the treatment. 
Participants were identified and recruited by a practising tissue viability nurse in a National Health 
Service board following ethical approval for the research. Qualitative evidence synthesis (QES) was 
then used to develop a comprehensive patient aspects section for the HTA report (10). This section 
identified patient communication and education issues, as well as outcomes of importance to 
patients. For example, while wound healing was the most important outcome to patients, 
controlling the signs and symptoms - such as odour, exudate and pain – and preventing infection and 
wound deterioration were also important outcomes.  
 
This robust evidence base enabled patients’ perspectives and experiences to guide 
recommendations with three of the recommendations incorporating the needs and values identified 
in the QES. This additional evidence source also enabled HTA researchers to have sufficient evidence 
to develop consensus guidance and make recommendations (10).  
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The impact of patient involvement continued beyond publication of the recommendations as the 
patient-based evidence guide a short life implementation working group, the creation of a patient 
version of the HTA report (12) and guidance for Scotland’s National Health Service (NHS Scotland) 
and staff training materials. While such an outcome is persuasive of the impact and potential value 
of patient involvement in HTA, it also highlights the urgent need to develop this methodology so that 
it can be used in more rapid HTAs which account for most HTAs in Scotland.  
 
Patient-based evidence for obstructive sleep apnea (CADTH) 
Over the past few years, CADTH has made a concerted effort to enhance how it incorporates the 
patient voice within projects related to medical devices and clinical interventions (13). Direct 
engagement has been challenging as there are not always obvious patient groups to involve when 
conducting HTAs, for example when assessing diagnostic or screening interventions. As a result, 
CADTH has explored using QES of patient-based evidence in assessments such as the Optimal Use 
assessment of interventions for the treatment of obstructive sleep apnea (OSA) in adults (14).  
 
An Optimal Use assessment aims to encourage the appropriate use of a health technology by 
considering the clinical and cost-effectiveness, safety, and patients’ experiences of the intervention 
(13). Additionally, it addresses ethical issues, implementation considerations, and any potential 
environmental impacts. Optimal Use assessments are reviewed by CADTH’s Health Technology 
Expert Review Panel for recommendation  
 
The QES considered the perspectives and experiences of patients, their family members, and their 
non-clinical caregivers about interventions for the treatment of OSA. This included positive airway 
pressure therapies such as continuous positive airway pressure (CPAP), oral appliances, surgical 
interventions and lifestyle modifications, such as diet and exercise. From the resulting thematic 
synthesis, two primary themes emerged. The first theme identified a range of factors that influence 
whether people seek and initiate treatment for OSA. For example, the review highlighted factors 
that might prevent people from seeking a diagnosis or starting treatment such as risk awareness and 
fear. It also stressed the importance of family, spouses or partners in encouraging diagnosis in the 
first place. The second theme reflected that all the interventions for OSA are inconvenient, 
uncomfortable and require considerable adaptation to daily routines. Some people living with OSA 
can adapt and incorporate interventions into their lives, although others cannot. This leads to low 
compliance despite great effort. Support of family members and caregivers again emerged as 
important in this process. 
 
The QES contributed to the HTA in three major ways. First, the findings allowed for a better 
understanding of the clinical findings – in particular, how the interventions were used and how this 
could affect the assessment of the effectiveness of the intervention. In particular, the QES 
challenged assumptions in the context of compliance as it remains unclear whether some people do 
not observe a positive effect because they cannot comply with their treatment, or whether they do 
not comply because they do not observe a positive effect. Secondly, the synthesis informed the 
recommendation generated by the expert committee, i.e. people with moderate or severe OSA 
should first try CPAP and then if they cannot tolerate it, consider a mandibular appliance. Thirdly, 
the review helped to identify important implementation considerations. For example, at times there 
is insufficient instruction provided on how to use and care for CPAP machines or oral appliances 
which can affect compliance and effectiveness.  
 
Recognition of the added value of QES of patient aspects has resulted in its wider use in CADTH and 
an understanding that the influence of patient-based evidence varies across HTA topics. Currently, 
the syntheses are conducted in parallel with other evidence gathering which is partly due to 
aggressive timelines. However, CADTH is exploring whether this type of review should be done 
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earlier, perhaps during the scoping phase to better inform the entire assessment. Using QES to 
explore relevant patient aspects is a rapidly evolving aspect of CADTH’s work and has been very well 
accepted by expert committees. 
 
Patient input in TNF-alpha inhibitors (NICE) 
It is likely that HTA bodies and the patients and patient groups that take part in HTAs, may at times 
have different perspectives about how and when patient involvement added value to an HTA. An 
example is drawn from a case study prepared by a patient group, the National Ankylosing Spondylitis 
Society (NASS), following its participation in a National Institute for Health and Care Excellence 
(NICE) HTA of TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis (15). NASS 
recorded the case study to enable other patient groups to learn from their experience. 
 
The case study suggests that to have impact, a patient group needs to undertake considerable work 
before, during and after the initial assessment. NASS identified the need to keep up to date with 
therapy developments in its areas, including monitoring the medical advisory board and the latest 
clinical research papers and attending conferences. NASS also gained a solid understanding of the 
needs of people living with ankylosing spondylitis in the UK by conducting surveys every three years 
with their members, taking 5000 calls per year on their helpline, speaking to members at an annual 
members’ day and awareness events around the UK and interacting through social media. This 
preparation enabled NASS to provide an informed response within the short timelines when NICE 
announced the appraisal. 
 
NASS drew on its knowledge base when completing the NICE template for patient group submissions 
to provide information about the impact on daily life of ankylosing spondylitis, but also ran an online 
survey with their members during the submission period to identify patient views on specific issues, 
such as iv infusion and sequential treatment. For example, the online survey used closed questions 
to gather statistics such as the number of patients currently on anti TNF therapy and open questions 
which could be analysed to gain a greater understanding of the advantages and disadvantages of 
treatment options. The survey was open for four weeks and attracted 608 responses. When the data 
was analysed, it provided NASS with useful statistics, themes and illustrative quotes.  
 
Following a review of the evidence and submissions, NICE published its draft recommendations in is 
Appraisal Consultation Document (16). At this point, NASS had 20 days to comment on the draft 
recommendations which included two important areas for people with ankylosing spondylitis that 
were negative. First, infliximab was not recommended for the treatment of ankylosing spondylitis. 
Secondly, treatment with another anti TNF therapy was not recommended for people whose disease 
had not responded to treatment with the first anti TNF therapy, or those who had an initial response 
which was then lost. 
 
In response to the draft recommendations, NASS conducted another survey with members on these 
two issues, particularly seeking the views of people who had switched anti TNF therapies, reasons as 
to why they had switched, and how beneficial this switch had been. The survey was open for only 
eight days due to the consultation deadline, but attracted 858 responses which provided statistics 
and quotes to clarify patients’ experiences and needs. 
 
From this data, NASS was able to provide a slide presentation (including graphs and quotes from 
patients) for the NICE expert committee on the sequential use of anti-TNF therapies and the specific 
people/populations who might benefit from infliximab because it was not a self-administered 
treatment. These included people with memory loss, learning disabilities, dexterity problems, or a 
fear of needles. 
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These real-life data resulted in the negative recommendations being changed as follows. 
 
Extracts from the final guidance 
Patient evidence paragraphs (guidance 4.22, 4.23, 4.24) 
• There is also anecdotal evidence suggesting that a second or third TNF-alpha inhibitor can be 
clinically effective if the first has failed. 
• [Infliximab] might benefit people with memory problems, learning disabilities, dexterity 
problems, or a fear of needles. (15) 
 
Patient input – submissions, surveys and representatives (CONITEC) 
In Brazil, community participation is stipulated as a right in the Brazilian Federal Constitution and 
other laws, including those related to the Brazilian Public Health System (SUS). The Law 12,401/2011 
created the National Committee for Health Technology Incorporation (CONITEC) and formalized PPI 
in the SUS HTA process through: 
• public consultations for all recommendations about the inclusion, exclusion or modification 
of health technologies; 
• public hearings, depending on the assessment (not yet undertaken);  
• the participation of the National Health Council, which represents citizens and users of SUS, 
as a member of CONITEC (17). 
Usually, CONITEC recommendations are submitted for public consultation for 20 days, but 
consultation can be prolonged. Anyone can provide comments on the recommendations if they 
identify themselves. 
 
In 2014, a consultation form specifically for the public was created to capture the patient and 
caregiver perspectives of the technologies being assessed. Currently, there are two forms for public 
consultation comments available online. The first, seeking technical and scientific information, is 
usually completed by health professionals, industry and the general public. The second aims to 
capture opinions or experiences and is completed by patients, caregivers and health professionals 
(18).  
 
The number of submissions received from patients and the public is one measure of patient 
involvement impact (18). In 2014, CONITEC began to disseminate a list of upcoming public 
consultations on its website and e-mail lists and partner’s social media. This resulted in a more than 
400% increase in submissions annually; from 2,584 submissions in 2014 to 13,619 submissions in 
2015. This figure was influenced by two topics - beta interferon 1-a in multiple sclerosis (19) and 
cesarean section (20) - which attracted 4,846 submissions and 3,706 submissions respectively. 
However, an exponential increase can still be noticed if these two topics are excluded. 
 
Between January 2012 and June 2017, CONITEC performed 219 public consultations, receiving more 
than 30,000 submissions with more than half of these from SUS users. Since 2015, CONITEC has 
produced summary versions of its technical reports for the public and patients in plain language to 
aid understanding of the reports and enable patients to contribute more easily. This tool may also 
have contributed to the increase in community participation.  
 
To investigate patient needs and preferences, CONITEC began conducting patient surveys in 2015 to 
inform its Clinical Protocols and Therapeutic Guidelines (PCDT). By June 2017, 13 surveys had been 
completed. Patients provided information about their diseases and made suggestions, such as 
healthcare improvements, appeals for new technologies and aspects that in their perspective 
critically needed addressing in the PCDT. 
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In 2014 and 2015, patient representatives took part in CONITEC’s plenary sessions aimed at solving 
issues related to the use of technology including “Budesonide and Formoterol in aerosol for the 
treatment of asthma” (18). One of the patient representatives taking part in a plenary session, a 
guest patient representative of the Brazilian Association of Asthmatics (Associação Brasileira de 
Asmáticos - ABRA), reported the difficulties faced by patients to control the disease, the high cost of 
treatment and, most importantly, the educational process needed for safe and correct use of 
medicines. The patient representative ratified the similar efficacy of the analyzed technologies and 
identified education as the most important issue as patients were often unaware of how to correctly 
use medical devices in asthma. 
 
Conclusion 
 
Reflections on the case studies 
These observations from people experienced in patient involvement in HTA bodies provide specific 
case studies that use different patient involvement approaches and reflect on their impact in HTA. 
The story from CONITEC describes increasing the number of written submissions from patients as a 
measure of impact and highlights the role patients can play in identifying issues that matter most to 
patients, such as education about the correct use of a health technology. The story teller makes a 
link between the implementation of communication tools – such as disseminating information about 
upcoming consultations and preparing plain language guides to technical reports – and achieving the 
impact of increased patient participation. 
 
In the CADTH story, patient involvement was described as an important source of evidence to inform 
an assessment with patient-based evidence revealing patient behaviours when seeking treatment 
and using the health technologies, as well as educational needs. The story teller makes a link 
between conducting QES on patient needs and preferences and achieving the impact of adding 
information which can test assumptions and address gaps in the clinical and cost effectiveness 
evidence. This is consistent with findings that patient involvement can provide useful information in 
an HTA when there are uncertainties and gaps in the literature (21).  
 
The SHTG story, demonstrates the value of using primary and secondary research into patients’ 
needs, preferences and experiences to determine the optimal use of a health technology. It 
highlights that secondary research may only identify condition specific information and that primary 
research may be needed to answer specific research questions relating to patients’ perspectives and 
experiences of using the health technology in the local health system. It suggests patient 
involvement can be especially valuable when there is a paucity of clinical and economic evidence 
and has an important role for HTAs of non-medicines and medicines. The storyteller makes the link 
between patient involvement and impact of the inclusion of recommendations in the HTA report 
which reflect their words, needs and preferences. Finally, this story teller links patient involvement 
with a wider impact on the HTA process with patient involvement requiring the development and 
incorporation of appropriate methodologies, influencing questions that can be asked and the 
evidence assessed in future HTAs.  
 
The experience of NASS and NICE also points to the potential for patient involvement to enable HTAs 
to make more informed recommendations by providing data that was not available in the published 
literature. This story teller emphasised a link between the patient organizations preparation, 
responsiveness and ongoing involvement in the HTA and the impact of changing the 
recommendation to take account of the experiences of patients who would use the treatment, and 
the differing needs of patients with the same condition. 
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It is noteworthy, that although the NICE case study resulted in changing a negative recommendation 
for a medicine to a positive recommendation, the common theme to each example provided is that 
of greater information about patients’ lives leading to improved decisions about how and when a 
health technology is used. Additionally, while patient involvement is sometimes considered an 
additional cost and burden lacking methodology, these examples suggest that HTA bodies may make 
better informed decisions using documented practices such as patient submissions and robust 
methodologies such as QES.  
 
Without patient involvement could SHTG have developed consensus guidance on the optimal use of 
antimicrobial wound dressings? Without patient involvement could CADTH and CONITEC have 
identified the most important issues for sleep apnea and asthmatic patients respectively? And 
without the data collected by NASS, how could NICE have identified sub-groups not identified in the 
clinical trials who could benefit from a treatment. As work continues to develop the tools to evaluate 
the impact of patient involvement in HTA, it may also be worth considering the impact of omitting 
patient involvement.  
 
Other evaluations of impact 
The term ‘impact’ lacks definition and is used interchangeably with influence in the literature. It can 
be linked with achieving a goal (5) or fulfilling a purpose which is evidenced by a range of outcomes 
such as the decisions made, behaviour changed and knowledge gained (24). While this paper focuses 
on a positive impact, unintended consequences and negative impacts are also an important part of 
measuring impact. Identifying the impact of patient involvement may depend on locating outcomes 
or actions “that can be credibly linked to” (24) the goal or intent of patient involvement. 
Furthermore, the stories presented in this paper are just one example of impact evaluation. Each 
HTA body uses other processes. 
 
To understand the impact of patient involvement, HTA bodies need to document its use and 
influence (4). An evaluation of Danish HTAs points to how this information should be documented 
such as including a section on patient aspects in the HTA report to enable others to determine how 
patient aspects were addressed, the kind of data included and how it was generated, and if it was 
integrated in the conclusion (22). Similarly, all National Institute for Health Research (NIHR) projects 
require a section in their annual reports detailing how patients were involved and the difference it 
made (23) and the HTAi Values and Quality Standards for Patient Involvement in HTA requiring HTA 
bodies to report the influence of patient contributions on conclusions and decisions in each HTA 
forms part of the CADTH’s framework for patient engagement in HTA (13). 
 
As SHTG rarely undertakes full HTAs it is not possible to fully evaluate the impact of patient 
involvement across these reports. However, the HTA report documents the methods for primary and 
secondary research into patient aspects, identifying key findings. The final recommendations then 
document whether they have arisen from the patient aspects section. Furthermore, each full HTA is 
evaluated according to a logic model that has been developed to guide all SHTG work. A new process 
for targeted patient involvement in more rapid HTAs has been developed and an evaluation 
framework process is being developed. 
 
At CADTH, a recent independent evaluation of patient involvement in medicine HTAs, specifically the 
Pan-Canadian Oncology Drug Review, included interviewing expert committee members, agency 
staff and patient groups to explore different expectations for patient involvement and if these have 
been met (25). It also measured impact against set goals defined by the participants, rather than 
external criteria, to explore variable achievement of democratic and scientific goals. 
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At NICE, the impact of most patient involvement has not been routinely documented or evaluated; 
rather its contribution has been noted (how) when it has provided new insight, such as changing a 
comparator, or real-life data to answer a question in the absence of published (or existing) evidence. 
However, since February 2016, NICE has systematically captured the impact of patient input in two 
types of HTAs: the interventional procedures and ultra-orphan programmes. This is to identify the 
most effective methods of patient involvement, provide examples of what works well, and to inform 
feedback letters to patient organizations of their involvement and subsequently help strengthen any 
future involvement. 
 
Meanwhile, in addition to other processes described in this paper, CONITEC has an ongoing 
partnership with the Oswaldo Cruz Foundation (Fiocruz) School of Governance in Health based in 
Brasilia to enable the systematic measurement of impact of the public and patient involvement (PPI) 
at all (local, regional and national) levels. 
 
Future use of impact stories 
Personal stories have a role to play in reflecting on the impact of patient involvement in HTA, 
enabling evidence to be collected on activities individuals link to patient involvement, potentially 
enabling a wider understanding of the construct of impact in patient involvement. Future research 
should explore stories of the impact of patient involvement in HTA that come from all stakeholders 
involved in HTA, particularly patients and their representative groups and HTA decision makers. This 
could consider short and long-term impacts and the way in which patient involvement changes HTA 
bodies and patient organizations, HTA processes and industry. 
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Table 1 HTA bodies and speakers who took part in the workshop panels 
 
Panel 1: How/when research into patient aspects and patient-based evidence is making a difference to an 
HTA or HTAs 
HTA body Speaker 
CADTH – Canadian Agency for Drugs and Therapies in Health  Michelle Mujoomdar  
DEFACTUM (Denmark) Camilla Palmhøj Nielsen 
AGENAS -National Agency for Regional Health Services (Italy) Alessandra Lo Scalzo 
SHTG - Scottish Health Technologies Group, Quality Improvement 
Scotland  
Karen Facey for Naomi Fearns 
 
Panel 2: How/when patient participation is making a difference to an HTA or HTAs 
HTA body Speaker 
PBAC - Pharmaceutical Benefits Advisory Committee (Australia) Jo Watson 
CONITEC - National Committee for Health Technology Incorporation 
(Brazil) 
Aline Silveira Silva 
NICE - National Institute for Health and Care Excellence (England) Heidi Livingstone 
CDE - Division of Health Technology Assessment, Center for Drug 
Evaluation (Taiwan) 
Grace Huang 
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Table 2: Summary of organizations and their processes 
Organization Canadian Agency for Drugs 
and Technologies in Health 
National Committee for Health 
Technology Incorporation 
(Comissão Nacional de 
Incorporação de Tecnologias 
no SUS) 
The National Institute for 
Health and Care Excellence 
Scottish Health Technologies 
Group, Healthcare 
Improvement Scotland 
Abbreviation CADTH CONITEC NICE SHTG 
Jurisdiction Canada Brazil England Scotland 
Function To provide health care 
decision-makers with objective 
evidence to inform decisions 
about the optimal use of 
health technologies1 
To advise the Brazilian 
Ministry of Health in decisions 
related to the incorporation, 
exclusion or change of 
medicines, products and 
procedures in the Brazilian 
Public Health System (SUS).2 
To provide national guidance 
and advice to improve health 
and social care, including 
assessing the clinical and cost 
effectiveness of health 
technologies, such as new 
pharmaceutical and 
biopharmaceutical products, 
procedures, devices and 
diagnostic agents. to ensure 
that all National Health Service 
patients have equitable access 
to the most clinically - and 
cost-effective treatments that 
are viable. 3 
To provide NHSScotland 
boards with advice on the 
evidence about the clinical and 
cost effectiveness of existing 
and new technologies – 
excluding medicines - likely to 
have significant implications 
for patient care in Scotland. 4 
                                                          
1 CADTH. 2019. CADTH Framework for patient engagement in Health Technology Assessment. https://www.cadth.ca/cadth-framework-patient-engagement-health-
technology-assessment  
2 Silva AS, Petramale CA, Rabelo RB, Santos VCC. Brazil. In: Facey KM, Hansen HP, Single ANV, eds. Patient involvement in health technology assessment. Singapore: 
Springer Nature; 2017: 243-246. 
3 National Institute for Health and Care Excellence 2019. What we do. https://www.nice.org.uk/about/what-we-do 
4 Health Improvement Scotland. n.d. Scottish Health Technologies Group. 
http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg.aspx 
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Patient 
involvement 
approaches 
(bold indicates 
used in story) 
• Stakeholder feedback on 
included studies, draft 
report and 
recommendations 
• Patient group submissions 
(individual patient 
submissions if no group) 
• Literature synthesis, QES 
• One or two public, no 
patient, expert committee 
members5 
• Public consultation (online 
form for public, patients 
and caregivers) 
• Surveys - Clinical Protocols 
and Therapeutic Guidelines 
• Patient representatives 
(plenary sessions). 
• Scoping consultation with 
patient groups 
• Patient group and patient 
expert submissions 
• Lay member and invited 
patient expert participation 
in committee meetings 
• Open, public meetings 
• Consultation on draft 
recommendations 
• Appeal 
• Plain language reports 
• Patient groups consulted 
regarding need to review 
guidance6 
• Open topic proposal process 
• Patient group submissions 
• Targeted patient group 
consultation 
• Public Partner membership 
of SHTG 
• expert advisory committee 
membership by invitation 
• Open, public meetings 
• Primary patient aspects 
research 
• Literature synthesis, QES 
• Plain language report7 
Type of HTA/s in 
story 
Optimal Use, Device  
(14 months) 
Multiple including rapid 
medicine HTA (180 days) and 
clinical guidelines 
Multiple technology appraisal 
(60 weeks) 
Full, non-medicines HTA 
(approximately 1.5-2 years) 
Story topic Obstructive sleep apnea Multiple TNF-alpha inhibitors for 
ankylosing spondylitis and 
axial spondyloarthritis 
Antimicrobial wound dressings 
in patients with chronic leg 
ulcers 
  
                                                          
5 Weeks L, MacPhail E, Berglas S, Mujoomdar M. Canada. In: Facey KM, Hansen HP, Single ANV, eds. Patient involvement in health technology assessment. Singapore: 
Springer Nature; 2017: 247-264. 
6 Thomas V, Livingstone H, Norburn L, Thomas L, Leng G. England. In: Facey KM, Hansen HP, Single ANV, eds. Patient involvement in health technology assessment. 
Singapore: Springer Nature; 2017: 275-288. 
7 Single ANV, Macpherson K, Fearns N, Dickson J and Facey KM. Scotland. In: Facey KM, Hansen HP, Single ANV, eds. Patient involvement in health technology assessment. 
Singapore: Springer Nature; 2017: 321-332. 
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Result • Evidence about patient 
behaviours and need which 
addressed critical gaps 
• Increased participation 
• Information about patient’s 
information needs 
Change to recommendation 
based on patient group 
identified sub-group not 
identified in clinical trials. 
• Evidence of outcomes 
valued by patients and 
patient need enabled a 
guideline to be produced 
• Challenge to organization’s 
concept of evidence 
• Work to develop processes 
to enable robust patient-
based evidence to be used in 
rapid timelines. 
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